Turku University Hospital is a hospital in Turku, Finland.

There are 900 beds in Turun yliopistollinen keskussairaala.

During the past decade, Turun yliopistollinen keskussairaala conducted 30 clinical trials. In the 10-year time frame, 30 clinical trials started and 13 clinical trials were completed, i.e. on average, 43.3% percent of trials that started reached the finish line to date. In the past 5 years, 13 clinical trials started and 8 clinical trials were completed. i.e. 61.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Turun yliopistollinen keskussairaala" #1 sponsor was "Bayer" with 7 trials, followed by "Boehringer Ingelheim" with 7 trials sponsored, "Hoffmann-La Roche" with 2 trials sponsored, "Medtronic Neurovascular Clinical Affairs" with 2 trials sponsored and "Merck Sharp & Dohme LLC" with 2 trials sponsored. Other sponsors include 9 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Turun yliopistollinen keskussairaala" #1 collaborator was "Eli Lilly and Company" with 4 trials as a collaborator, "Eisai Inc." with 2 trials as a collaborator, "Medtronic Bakken Research Center" with 2 trials as a collaborator, "Central European Myeloma Study Group" with 1 trials as a collaborator and "DSMM (Deutsche Studiengruppe Multiples Myelom)" with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "Turun yliopistollinen keskussairaala" are "Atrial Fibrillation" (2 trials), "Cancer" (2 trials), "Carcinoma, Renal Cell" (2 trials), "Diabetes Mellitus, Type 1" (2 trials) and "Diabetes Mellitus, Type 2" (2 trials). Many other conditions were trialed in "Turun yliopistollinen keskussairaala" in a lesser frequency.

Most popular intervention types in "Turun yliopistollinen keskussairaala" are "Drug" (27 trials), "Device" (5 trials), "Biological" (1 trials), "Combination Product" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "Abrocitinib 200 mg" (2 trials), "Belzutifan" (2 trials), "Empagliflozin" (2 trials) and "Lenvatinib" (2 trials). Other intervention names were less common.

The vast majority of trials in "Turun yliopistollinen keskussairaala" are 31 trials for "All" genders, 2 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Turun yliopistollinen keskussairaala". undefined are not yet recruiting, 9 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 16 completed trials in Turun yliopistollinen keskussairaala, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Turun yliopistollinen keskussairaala, 1 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 19 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 0 trials that are defined as “Not Applicable".

Turun yliopistollinen keskussairaala has several departments that took part in Clinical trials: "Turku Uni Central Hospital; Oncology Clinics" - 11 trials, "Heart Center, Turku University Hospital" - 9 trials, "Perioperative Services, Intensive Care and Pain Therapy, Turku University Hospital" - 7 trials, "Department of Pediatrics, Turku University Hospital" - 6 trials, "Department of Urology" - 4 trials, "Turku Children's Hospital" - 3 trials, "Department of Obstetrics and Gynecology, Turku University Hospital" - 2 trials, "Turku University Hospital, Paediatric and Adolescent Haematology and Oncology" - 2 trials, "Turku University Hospital, Clinical Haematology and Stem Cell Transplantation Unit" - 2 trials